SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

F O R M 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR

15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of December, 2012

 

Prana Biotechnology Limited

(Name of Registrant)

 

 

Level 2, 369 Royal Parade Parkville  Victoria  3052 Australia

(Address of Principal Executive Office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-Fx Form 40-F ¨

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):_____

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):_____

 

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

 

Yes ¨ No x

 

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- ____

 

 

 

 

 

 

 

PRANA BIOTECHNOLOGY LIMITED

 

 

6-K Items

 

1. Results of Annual General Meeting

 

 

 

 

 

 

PRANA BIOTECHNOLOGY LIMITED

(ASX: PBT)

 

RESULTS OF ANNUAL GENERAL MEETING

 

 

Wednesday, 12^th December 2012

 

The Company wishes to advise that all resolutions contained in the Notice of Meeting were carried on a show of hands.

 

In accordance with Listing rule 3.13.2 and Section 251AA(1) of the Corporations Act 2001, the following information is provided in relation to the resolutions considered by Members of the Company at the Annual General Meeting held today.

 

														Total Valid
Resolutions		For			Against			Abstain			Proxy's			Proxies
											Discretion*			Received
1    Non-binding Resolution - Remuneration Report			55,340,575			2,876,299			21,971,001			9,535,592			89,723,467
2    Re-Election of Non-Executive Director - Dr George Mihaly			59,689,370			529,919			1,638,500			27,864,478			89,722,267
3A Ratification of previously issued securities - ATM			56,049,423			4,370,866			1,457,500			27,844,478			89,722,267
3B Ratification of previously issued securities - Private Placement			18,921,934			4,522,666			41,581,827			24,695,840			89,722,267
4    Approval to refresh employee share plan			54,185,016			6,155,496			19,848,943			9,532,812			89,722,267
5A Issue of Unquoted Options to Mr Geoffrey Kempler			46,730,376			13,570,136			19,888,943			9,532,812			89,722,267
5B Issue of Unquoted Options to Mr Brian Meltzer			45,763,526			14,536,986			19,888,943			9,532,812			89,722,267
5C Issue of Unquoted Options to Mr Peter Marks			45,759,436			14,537,416			19,892,603			9,532,812			89,722,267
5D Issue of Unquoted Options to Dr George Mihaly			45,925,916			14,399,619			19,882,693			9,514,039			89,722,267
5E Issue of Unquoted Options to Mr Lawrence Gozlan			45,771,856			14,548,679			19,887,693			9,514,039			89,722,267
6   Issue of Unquoted Options to Mr Richard Revelins			46,991,543			13,698,769			1,206,250			27,825,705			89,722,267
7  Approval of 10% Share Placement Facility (new ASX rule)			54,877,876			5,604,229			1,414,457			27,825,705			89,722,267

 

* The Chairman voted undirected proxies in his control in favour of all resolutions.

 

On behalf of the Board

 

Richard Revelins

Company Secretary

Prana Biotechnology Limited

 

 

 

 

SIGNATURES

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

 

	PRANA BIOTECHNOLOGY LIMITED
	(Registrant)
	By:	/s/ Geoffrey Kempler
		Geoffrey Kempler, Executive Chairman

 

December 12, 2012